Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 10, 2006, Pages 1619-1624

  Georgiades, Christos S ^a   Liapi, Eleni ^a   Frangakis, Constantine ^a   Park, Ju Un ^a   Kim, Hyung Woo ^a   Hong, Kelvin ^a   Geschwind, Jean Francois H ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MDS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTETAN; CISPLATIN; CLINDAMYCIN; DOXORUBICIN; EMBOSPHERE; ETHIODIZED OIL; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN C; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BARCELONA CLINIC LIVER CANCER STAGING SYSTEM; CANCER OF THE LIVER ITALIAN PROGRAM STAGING SYSTEM; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH STAGING SYTEM; CHINESE UNIVERSITY PROGNOSTIC INDEX; FEMALE; GROUP D ETUDE DE TRAITEMENT DU CARCINOMA HEPATOCELLULAIRE STAGING SYSTEM; HUMAN; INTERMETHOD COMPARISON; JAPANESE INTEGRATED STAGING; LIVER CANCER STUDY GROUP OF JAPAN STAGING SYSTEM; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE STAGING SYSTEM; OKUDA STAGING SYSTEM; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TOKYO STAGING SYSTEM;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33750075017     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000236608.91960.34     Document Type: Article

References (18)

1. Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359:1734-1739.
2. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54.
3. Lo CM, Ngan H, Tso WK, et al. Randomized control trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171.
4. Grieco A, Pompili M, Caminiti G, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing nonsurgical treatment: comparison of Okuda, CLIP and BCLC staging systems in a single Italian centre. Gut 2005; 54:411-418.
5. Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15:1209-1218.
6. Testa R, Testa E, Botta F, et al. Transcatheter arterial chemoembolization in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD) in predicting outcome after treatment. Aliment Pharmacol Ther 2003; 17:1563-1569.
7. Yuen MF, Chan AO, Wong BC, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol 2003; 98:1181-1185.
8. Biselli M, Andreone P, Gramenzi A, et al. Transcatheter arterial embolization therapy for patients with hepatocellular carcinoma: s case-controlled study. Clin Gastroenterol Hepatol 2005; 3:918-925.
9. Cox D. Regression models and life tables (with discussion). J R Stat Soc Ser B 1972; 34:187-220.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
11. Tukey JW. Bias and confidence in not quite large samples. Ann Math Stat 1958; 29:614.
12. Georgiades CS, D'Angelo M, Hong K, et al. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16:1653-1659.
13. Geschwind JF, Ramsey DE, van der Wal BC, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003; 26:111-117.
14. Kurokohchi K, Takaguchi K, Kita K, et al. Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. World J Gastroenterol 2005; 11:5401-5403.
15. WHO Handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979;48.
16. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. EASL Panel of Experts on HCC. J Hepatol 2001; 35:421-430.
17. Franca AVC, Elias JJ, Lima BLG, et al. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004; 37:1689-1705.
18. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J 2003; 79:307-12.